Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 3 of 3)
Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes. After the break, the trio looks ahead to sustained TKI therapy via EYP-1901 (Duravyu, EyePoint Pharmaceuticals) by examining data from the DAVIO-2 study.
Drs. Sridhar, Borkar, and Weng are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Borkar, and Weng for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.
--------
28:51
--------
28:51
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 2 of 3)
Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins guests Maggie Runner, MD, and Veeral Sheth, MD, MBA, to translate key data into clinic-ready tactics. They unpack how volatility—not just volume—of fluid correlates with outcomes, which fluid compartments matter most, and why durability reduces “yo-yo” anatomy.
Drs. Sridhar, Runner, and Sheth are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Runner, and Sheth for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.
--------
27:04
--------
27:04
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 1 of 3)
In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about retinal fluid fluctuation as a modifiable driver of outcomes in neovascular AMD and DME. The panel defines fluctuation across compartments, examines practical barriers to longitudinal OCT tracking, and assesses the undertreatment gap in real-world practice.
Drs. Sridhar, Mammo, and Sarraf are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Mammo, and Sarraf for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.
--------
29:02
--------
29:02
Global Discussions in GA: Educating Patients and Encouraging Follow-Up
How are the world's leading mind on GA management educating patients about GA so they follow-up with their providers? Host Anat Loewenstein, MD, convenes a roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, to review their specific approaches to GA management, patient conversations, and education for patients and caregivers. Plus, are AREDS supplements an option for GA patients?
--------
22:49
--------
22:49
Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring
At what point in their disease do world-renowned retina specialists want to see patients with GA? Host Anat Loewenstein, MD, leads a candid roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, on modern referral patterns, monitoring intervals, and fellow-eye surveillance. The panel explores the utility of OCT and FAF imaging, discusses patient/caregiver education, and the promise of AI tools in caring for GA patients.
Netherlands